Annovis Bio, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $14.8 million, or $0.40 per share, compared to a net loss of $6.2 million, or $0.32 per share, for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $32.4 million, up from $11.8 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $12.0 million in the second quarter, a 132% increase from $5.2 million in the same quarter of 2025. Total operating expenses for the quarter reached $14.4 million, compared to $6.3 million in the previous year.
The company's financial position has also changed significantly, with total assets increasing to $22.0 million as of June 30, 2026, from $21.1 million at the end of 2025. However, total liabilities surged to $26.3 million, primarily due to a substantial increase in warrant liabilities, which rose to $19.9 million from $0.6 million at the end of 2025. This increase reflects the company's ongoing financing activities, including multiple public offerings that have raised significant capital. As of June 30, 2026, Annovis had cash and cash equivalents of $18.7 million, a decrease from $19.5 million at the end of 2025.
Strategically, Annovis has been active in raising capital through various equity offerings. In April and May 2026, the company completed underwritten offerings that collectively raised approximately $24.6 million in net proceeds. Additionally, the company has been expanding its clinical trials, with ongoing studies for its lead drug candidate, buntanetap, aimed at treating neurodegenerative diseases such as Alzheimer's and Parkinson's. The company has treated over 1,600 patients and is currently conducting pivotal Phase 3 studies for both conditions.
Operationally, Annovis has seen a significant increase in its employee headcount, reflecting its expansion in clinical development and administrative functions. The company is also preparing for the initiation of an open-label extension study for Alzheimer's patients in October 2026, which will allow participants from previous trials to continue receiving treatment. Despite these advancements, the company has acknowledged substantial doubt regarding its ability to continue as a going concern, citing the need for additional capital to fund operations through at least the fourth quarter of 2026.
Looking ahead, Annovis anticipates continued losses as it ramps up clinical development programs and prepares for potential commercialization of its product candidates. The company is focused on securing additional funding through public or private equity offerings, debt financing, or other arrangements to support its ongoing operations and development efforts.
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative diseases, primarily Alzheimer’s and Parkinson’s. Its lead product candidate, buntanetap, is an oral small molecule designed to inhibit multiple neurotoxic proteins involved in disease progression, aiming to improve cognition and motor function. Annovis targets large aging populations with unmet medical needs through a drug development platform focused on disease-modifying treatments for chronic and acute neurodegeneration.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov